Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takeshi Yoda has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Longitudinal Changes in Utility Scores and Health-Related Quality of Life During Interferon-Free Direct-Acting Antiviral Therapy for Chronic Hepatitis C in Japan: Implications for Cost–Utility Analysis

    by Maki Hirao, Hiroki Sugimori, Ataru Igarashi, Hiroshi Yatsuhashi, Toshihiko Satoh, Shunya Ikeda, Naohiko Masaki, Hiroshi Yotsuyanagi, Tomoyuki Takura, Takeshi Yoda, et al.

    Background/Objectives: Interferon-free direct-acting antiviral (DAA) therapy cures chronic hepatitis C virus (HCV) infection, but its short-term effects on health-related quality of life (HRQoL) are captured differently by generic and disease-specific instruments. We examined longitudinal changes in utility scores and HRQoL in a multicenter Japanese cohort. Methods: Adults with chronic HCV completed the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L), the 8-Item Short-Form Health Survey (SF-8), and the Chronic Liver Disease Questionnaire (CLDQ) at baseline and at 12, 24, and 36 weeks after treatment initiation; 48-week data were included when available. Complete-case panels were analyzed for each instrument (SF-8, n = 112; CLDQ, n = 131; EQ-5D-5L, n = 128). Domain trajectories were summarized and compared with baseline. Results: By week 36, SF-8 general health improved significantly from 50.42 to 52.47, whereas vitality (50.73 to 52.55) and mental health (51.02 to 53.05) showed nonsignificant numerical increases. CLDQ showed improvements in worry (5.21 to 5.82) and total score (5.21 to 5.47). EQ-5D-5L utility values remained high and largely stable (0.913 to 0.920), suggesting ceiling effects in patients with relatively good baseline health status. External real-world evidence also suggested better on-treatment HRQoL with ribavirin-free regimens. Conclusions: In Japanese patients with HCV, interferon-free DAA therapy was associated with early improvements in symptom-proximal and mental domains of HRQoL. Generic utility scores changed little over the short term, indicating that disease-specific patient-reported outcome (PRO) instruments and utility measures should be used together for patient-centered assessment and cost–utility modeling.

  • Open Access

    Feasibility of Physiological Assessments for Long-Distance Swimming Safety in Open Water Using Virtual Reality Settings

    by Hiroki Hamada, Yuko Nakao, Takashi Yamagata, Takayuki Torigoe, Chihiro Watanabe, Masato Kawashima, Eri Oyanagi, Makoto Tajima, Toshihiro Wakimoto, Takeshi Yoda, et al.

    Introduction: Approximately 240,000 people drown annually worldwide. The benefits of programs of long-distance swimming in the sea are important for children. However, due to safety concerns, fewer schools are implementing the programs. A better system for monitoring heart rate that enables the detection of physiological abnormalities and improves the safety of long-distance swimming is needed. In this feasibility study, a system was developed for an open-water setting. Furthermore, we explored acute stress responses using Virtual Reality (VR) as a potential screening tool. Methods: 40 healthy subjects (28 males, 12 females; age: 18 ± 0.4 years) were timed in the 400m breaststroke, and their peak oxygen uptake (peak VO 2 ) was measured; heart rate was monitored during long-distance swimming in the sea. Furthermore, cardiac autonomic nerve activity was measured during swimming VR exposure. Results: A significant correlation was observed between heart rate during long-distance swimming in the sea and the 400m breaststroke time (r = 0.46, p < 0.01), but not at peak VO 2 (r = -0.10, n.s.). A rapid increase in a subject's heart rate was observed immediately before fitting the buoyancy device. Sympathetic activity after VR exposure was significantly higher than before exposure ( p < 0.05). Discussion: Heart rate during long-distance swimming depends on swimming ability, not maximum aerobic fitness. Monitoring early heart rate spikes could assist in detecting physiological abnormalities. Furthermore, acute stress responses during VR exposure offer a safe screening method for collecting near-miss data in simulated environments. Conclusion: Real-time heart rate monitoring showed a relationship between swimming ability and heart rate in the sea. The swimming VR exposure demonstrated potential as an exploratory method for safe risk assessment, though its clinical value requires further validation.

  • Open Access

    Longitudinal Changes in Utilities and HRQoL During Interferon‑Free DAA Therapy for Chronic Hepatitis C in Japan: Implications for Cost‑Utility Analysis

    by Maki Hirao, Ataru Igarashi, Hiroshi Yatsuhashi, Toshihiko Sato, Shunya Ikeda, Naohiko Masaki, Hiroshi Yotsuyanagi, Tomoyuki Takura, Takeshi Yoda, Manabu Akazawa, et al.

    Background/Objectives: Direct‑acting antivirals (DAAs) cure hepatitis C virus (HCV) infection and may improve health‑related quality of life (HRQoL), but responsiveness differs across instruments. We quantified longitudinal changes using EQ‑5D‑5L, SF‑8 and CLDQ in a multicenter Japanese cohort. Methods: Adults with chronic HCV completed patient‑reported outcomes (PROs) at baseline and 12/24/36 weeks (48 weeks where available). Complete‑case panels were defined per instrument (SF‑8 n=112, CLDQ n=131, EQ‑5D‑5L n=128). Domain trajectories were summarized and compared with baseline. Results: SF‑8 improved by 36 weeks: General Health 50.42→52.47, Vitality 50.73→52.55, Mental Health 51.02→53.05. CLDQ improved in Worry 5.21→5.82 and Total 5.21→5.47. EQ‑5D‑5L utilities remained high and stable (0.913→0.920), consistent with ceiling effects at high baseline health. External real‑world data indicated better on‑treatment HRQoL with ribavirin‑free regimens. Conclusions: Interferon‑free DAAs yield early, clinically meaningful HRQoL gains in symptom‑proximal and mental domains, while generic utilities show minimal short‑term change. Combining disease‑specific PROs with utilities is essential for patient‑centered care and for parameterizing cost‑utility models in Japan.

  • Open Access

    Intra-Bone Marrow Administration of miR-140-3p Improves Bone Metabolism in a Growing Senescence-Accelerated Mouse Prone 6 Strain

    by Hironobu Katsuyama, Kazue Tanda, Kumiko Terada, Shigeko Fushimi, Takeshi Yoda, Vitalii Katsuyama, Tsutomu Nohno

    Background: Our previous study demonstrated that miR-140-3p induced osteocalcin expression in osteoblastic MC3T3-E1 cells. In this study, we investigated the direct effects of miR-140-3p on bone turnover in senescence-accelerated mice. Methods: In order to evaluate the effects of miR-140-3p, we formulated lipid nanoparticles (LNPs) containing miR-140-3p (100 μg/mL), with or without flotillin-2 (Flo2), a microvesicle marker excreted by osteoblasts. LNP was administered into the right tibia of the P6 strain of senescence-accelerated mice (SAMP6). Four-week-old SAMP6 males were divided into three groups: control, LNP, and LNP + Flo2. LNPs were administered five times, once every three days. No gait abnormalities were observed in any group. Two days after the last administration of LNPs, blood and urine samples were collected to measure bone turnover markers and blood chemistry and to perform urinalysis. Bone histomorphometry was performed on the left femur, contralateral to the administration site. The pancreas was removed for insulin staining of the Langerhans islets. Results: The LNP + Flo2 group showed greater bone volume, trabecular thickness, and osteoid thickness in bone histomorphometry. Carboxylated osteocalcin, a bone formation marker, was also higher in the LNP + Flo2 group, indicating that LNP + Flo2 activated osteoblastic function. Insulin levels in the islets of Langerhans did not differ across the groups, consistent with under-carboxylated osteocalcin levels. Conclusions: LNP + Flo2 effectively improved bone metabolism.

  • Open Access

    Willingness to Pay for COVID-19 Vaccines in Japan

    by Takeshi Yoda, Nagisa Iwasaki, Hironobu Katsuyama

    More than 80% of the Japanese population had received the coronavirus disease 2019 (COVID-19) vaccination by the end of April 2023; however, this vaccination rate continues to decline along with the need for booster shots. Further, the vaccines may not permanently be available free of charge. This study conducted a survey to determine the public’s willingness to pay for the COVID-19 vaccine in Japan. Using an internet research panel, the questionnaire collected data on various sociodemographic variables and the respondents’ willingness to pay for COVID-19 vaccines. Descriptive statistics and logistic regression analysis were used to evaluate the respondents’ answers. The results showed that of 1100 respondents, 55.2% would not want to receive the vaccine if it was paid for. A total of 44.8% respondents expressed willingness to pay, with most (170 respondents) willing to pay for 1000–1999 JPY (7.1–14.2 USD). Logistic regression analysis revealed that age, educational status, history of contracting COVID-19, and COVID-19 vaccination frequency were significantly associated with those who were willing to receive the COVID-19 vaccine if it was free (p < 0.05). These findings provide valuable insights for the Japanese government in determining appropriate pricing strategies to promote COVID-19 vaccination effectively.


  • Open Access

    Health state utilities of patients with hepatitis B and C and hepatitis-related conditions in Japan

    by Hiroki Sugimori, Maki Hirao, Ataru Igarashi, Hiroshi Yatsuhashi, Shunya Ikeda, Naohiko Masaki, Hiroshi Yotsuyanagi, Takeshi Yoda, Takeshi Odajima, Tomoyuki Takura, et al.

    Health state utilities are global measurements of quality of life and have been used to evaluate health outcomes for the cost-utility analysis. This study aimed to estimate the health state utilities of patients with hepatitis B (HB), hepatitis C (HC), and hepatitis-related diseases in Japan. We distributed a self-administered questionnaire, including the EuroQol 5-Dimension 5-Level (EQ-5D-5L), to 9,952 outpatients with several clinical conditions caused by HB or HC virus infection (such as asymptomatic chronic hepatitis, chronic hepatitis, compensated cirrhosis, and decompensated cirrhosis) and estimated the condition-specific utilities of patients with HB or HC. In patients with more severe conditions (patients with acute hepatitis, fulminant hepatitis, and hepatocellular carcinoma and patients undergoing post-liver transplantation), the utilities of these severe conditions were estimated by three hepatitis experts using the EQ-5D-5L. The means of the utilities for acute hepatitis, fulminant hepatitis, asymptomatic chronic hepatitis, chronic hepatitis, compensated cirrhosis, compensated cirrhosis, hepatocellular carcinoma stage I/II, hepatocellular carcinoma stage III/IV, and post-liver transplantation were 0.529, − 0.111, 0.904, 0.868, 0.845, 0.722, 0,675, 0,428, and 0.651 and 0.876, 0.821, 0.737, 0.671, 0.675, 0.428, and 0.651 in HB and HC, respectively. To the best of our knowledge, this is the first study that comprehensively assessed the health state utilities of patients with HB, HC and hepatitis-related conditions from a nationwide survey in Japan using the EQ-5D-5L.


  • Open Access

    The Relationship between Sources of COVID-19 Vaccine Information and Willingness to Be Vaccinated: An Internet-Based Cross-Sectional Study in Japan

    by Takeshi Yoda, Benjamas Suksatit, Masaaki Tokuda, Hironobu Katsuyama

    Despite considerable interest in the Japanese population in receiving the vaccine for COVID-19 when it first became available, a sizable percentage of people remain unwilling or hesitant to be vaccinated. Concerns among both the vaccinated and the unwilling center on the vaccine’s efficacy and its safety. Thus, this study aimed to identify whether the willingness to receive COVID-19 vaccination is related to the sources of information people use to learn about the vaccine. A cross-sectional study was conducted on 800 participants registered in an Internet research panel across Japan who completed a questionnaire on their sources of information about the vaccine, demographics, and vaccination status. Vaccine willingness/hesitancy and refusal were set as dependent variables in the logistic regression analysis, with sources of vaccine information and other socio-demographic variables set as independent variables. The results of the analysis found that the information sources significantly associated with willingness to vaccinate were TV (AOR 2.44 vs. vaccine refusal/hesitation), summary websites of COVID-19 by non-experts (AOR 0.21, vs. vaccine refusal/hesitation), Internet video sites (AOR 0.33, vs. vaccine refusal/hesitation), and the personal websites of doctors (AOR 0.16, vs. vaccine refusal/hesitation). Given the likelihood of misinformation in non-traditional sources of information, it is important that health communications be accurate and persuasive.


  • Open Access

    Analysis of People’s Attitude Toward COVID-19 Vaccine and Its Information Sources in Thailand

    by Takeshi Yoda, Benjamas Suksatit, Masaaki Tokuda, Hironobu Katsuyama

    Coronavirus disease 2019 (COVID-19) vaccine hesitancy has become a global problem. Therefore, we aimed to determine the relationship between the information sources on vaccines and the willingness of people to be vaccinated in Thailand. A sample of 500 respondents was drawn from an Internet research panel, and a questionnaire survey was administered to evaluate respondents’ willingness to be vaccinated by sex, age group, educational background, occupation, and presence of chronic diseases, as well as their information sources on COVID-19 vaccines. Descriptive statistics and logistic regression analysis were employed to assess the relationship between vaccine hesitancy/refusal and other variables. Our results demonstrated that 90.2% of the participants were either willing to vaccinate or were already vaccinated. By contrast, 6.0% were hesitant and 3.8% did not want to be vaccinated. Females, people with education less than master’s/bachelor’s degree or high school, day laborers, housewives, and unemployed were significantly related to vaccine hesitation/refusal. Furthermore, they were less likely than the vaccine willingness group to use information resources from the Ministry of Health, public health centers, or medical associations. As vaccine hesitancy and refusal ratio were found to be substantially lower than in a previous study for Thailand and other countries, public authorities should poll the public to identify vaccine-hesitant populations and their reasoning and provide appropriate information directly to the general public.


  • Open Access

    Can Muscle Mass Be Maintained with A Simple Resistance Intervention in the Older People? A Cluster Randomized Controlled Trial in Thailand

    by Bumnet Saengrut, Takeshi Yoda, Yumi Kimura, Yasuko Ishimoto, Rujee Rattanasathien, Tatsuya Saito, Kanlaya Chunjai, Kensaku Miyamoto, Kawin Sirimuengmoon, Rujirat Pudwan, et al.

    The aging population is rapidly increasing worldwide. Sarcopenia is a common and important health problem among older people. The prevalence of sarcopenia among older Thai adults is increasing. Exercise intervention for sarcopenia prevention may significantly improve muscle strength, body balance, and muscle mass. Therefore, this study aimed to investigate the effects of a simple resistance intervention (SRI) program in preventing sarcopenia on physiological outcomes among community-dwelling older Thai adults. This study was a 12-week randomized controlled trial, which included 80 community-dwelling older adults in Chiang Mai, Thailand, who were randomly assigned into control (40 participants who performed usual exercise) and intervention (40 participants who performed the SRI program) groups. The SRI program was a home-based program consisting of 30 min of resistance exercise three times/week for 12 weeks, health education on sarcopenia. After 12 weeks, all physiological outcomes were measured and were significantly improved in the intervention group compared with baseline; hand grip, skeletal muscle mass index, and walking speed were significantly improved in the intervention group compared with the control group. Based on our results, the SRI program may prevent muscle weakness in community-dwelling older people in Thailand.